 Be clear who is responsible for prescribing -ideally a single prescriber.  For an initial opioid trial, prescribe a short (1-2 week supply) of morphine immediate release tablets or liquid.
The patient may explore different doses within a specified range e.g. morphine 5-10mg. If reduction in pain is not achieved following a single dose of morphine 20mg, opioids are unlikely to be beneficial in the long term.  Initial positive outcomes do not predict outcomes in the longer term. A small proportion of patients may do well with opioids in the long term if the dose can be kept low and particularly if use is intermittent.  A trial period of FOUR weeks is adequate.  Do not exceed maximum recommended doses, without consulting a specialist service (see table and approximate opioid equivalences overleaf).  Discuss alternative strategies for exacerbations of pain -'short acting' opioids are not appropriate for the majority of patients.  Ensure that the dosing instructions are clear. The instructions for "as required" opioids must include a maximum daily dose. "As directed" is not acceptable.
Switching opioids
 Efficacy and adverse effects are similar for all opioids, though patients may tolerate one opioid better than another.  When switching, for safety reasons, consider reducing dose by 25-50% to allow for incomplete cross tolerance and monitor regularly. See table and approximate opioid equivalences overleaf.  Withdrawal symptoms (e.g. sweating, yawning and abdominal cramps) occur if an opioid is stopped/dose reduced abruptly. This is common with tramadol and can occur with weak opioids even after a short course.
Adverse effects
 Constipation: Common. Always prescribe laxatives. For example, a combination of stimulant laxative (bisacodyl) and stool-softener (docusate) and add an osmotic laxative (Laxido) if needed.  In addition, give lifestyle advice (fibre, fluid, toilet habit and exercise -more detail and patient information in appendix 1 of APC Laxative guideline). If constipation problematic with morphine, transdermal fentanyl is the preferred alternative.  Possible long term endocrine / immunological effects. Consider measuring plasma testosterone or oestradiol after 6 months, seek advice if levels low.
Dependence and addiction
 Physical dependence is inevitable. Addiction (psychological dependence and craving) is relatively rare.  Effects of physical dependence and ease of discontinuation helped by limiting max. dose (see overleaf). Higher doses by specialist recommendation or advice only Risk of harm/ mortality from oral morphine increases substantially at doses exceeding 120mg/day, but there is no increased benefit. *Tapentadol: For chronic pain in patients either unresponsive or unable to tolerate morphine, fentanyl, oxycodone and buprenorphine. Can be used 3rd line if the patient has not responded to morphine and buprenorphine and is showing symptoms of neuropathic pain. Key: Costs (in brackets) are from the Drug Tariff (Jun18) for 28 days treatment. Dose equivalences are approximate only. Regular monitoring and review is necessary to avoid both under dosing and excessive dosing. 
